Advertisement
Advertisement
IBRX
ImmunityBio, Inc. Common Stock
8.71
USDSponsored
+0.92
+11.81%
Jun 26, 16:00 UTC -4
Closed
After-Market
8.48
-0.23
-2.64%
IBRX Earnings Reports
Positive Surprise Ratio
IBRX beat 23 of 42 last estimates.
55%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$50.18M
/-$0.08
Implied change from Q1 26 (Revenue/ EPS)
+13.52%
/--
Implied change from Q2 25 (Revenue/ EPS)
+89.91%
/-20.00%
ImmunityBio, Inc. Common Stock earnings per share and revenue
On May 07, 2026, IBRX reported earnings of -0.08 USD per share (EPS) for Q1 26, missing the estimate of -0.07 USD, resulting in a -12.04% surprise. Revenue reached 44.21 million, compared to an expected 43.93 million, with a 0.63% difference. The market reacted with a -7.40% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 50.18 million USD, implying an increase of 0.00% EPS, and increase of 13.52% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were ImmunityBio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ImmunityBio, Inc. Common Stock reported EPS of -$0.08, missing estimates by -12.04%, and revenue of $44.21M, 0.63% above expectations.
How did the market react to ImmunityBio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -7.4%, changed from $8.38 before the earnings release to $7.76 the day after.
When is ImmunityBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for ImmunityBio, Inc. Common Stock's next earnings report?
Based on 4
analysts, ImmunityBio, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $50.18M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement